Fineline Cube

Follow:
14483 Articles
Cambrex Partners with Eli Lilly to Enhance Clinical Development for Biotech Collaborators
CompanyDeals

Cambrex Partners with Eli Lilly to Enhance Clinical Development for Biotech Collaborators

Dewpoint Therapeutics Partners with Mitsubishi Tanabe Pharma to Develop ALS Treatment
CompanyDeals

Dewpoint Therapeutics Partners with Mitsubishi Tanabe Pharma to Develop ALS Treatment

AstraZeneca's Imfinzi Receives FDA Approval for Limited-Stage Small Cell Lung Cancer
CompanyDrug

AstraZeneca’s Imfinzi Receives FDA Approval for Limited-Stage Small Cell Lung Cancer

Eli Lilly & Co. Expands Wisconsin Manufacturing Facility with $3 Billion Investment
Company

Eli Lilly & Co. Expands Wisconsin Manufacturing Facility with $3 Billion Investment

Amgen Expands Biomanufacturing Footprint in North Carolina with Second Facility
Company

Amgen Expands Biomanufacturing Footprint in North Carolina with Second Facility

Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral
CompanyDrug

Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral

CDE Approves RinuaGene's mRNA-Based RG002 for Clinical Study in Cervical Dysplasia
CompanyDrug

CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia

Burning Rock Ltd Reports Q3 2024 Financials with Revenue Growth and R&D Reduction
Company

Burning Rock Ltd Reports Q3 2024 Financials with Revenue Growth and R&D Reduction

Novavax to Sell Czech Manufacturing Facility to Novo Nordisk for $200 Million
CompanyDeals

Novavax to Sell Czech Manufacturing Facility to Novo Nordisk for $200 Million

China's Health Commission Issues Guidelines to Strengthen Ties Between Healthcare and Elderly Care
HospitalPolicy / Regulatory

China’s Health Commission Issues Guidelines to Strengthen Ties Between Healthcare and Elderly Care

Eli Lilly's Zepbound Outperforms Wegovy in SURMOUNT-5 Weight Loss Study
CompanyDrug

Eli Lilly’s Zepbound Outperforms Wegovy in SURMOUNT-5 Weight Loss Study

Phanes Therapeutics' PT217 Earns FDA Fast Track Designation for Neuroendocrine Prostate Cancer
CompanyDrug

Phanes Therapeutics’ PT217 Earns FDA Fast Track Designation for Neuroendocrine Prostate Cancer